Scholarlink

<p>Alzheimer’s disease (AD) remains a major neurodegenerative disorder with limited effective treatments, necessitating the search for novel acetylcholinesterase (AChE) inhibitors to mitigate cognitive decline. While synthetic inhibitors pose concerns regarding toxicity and bioavailability, natural compounds from <i>Aristolochia indica</i> present a promising yet underexplored alternative. This study employed molecular docking, molecular dynamics (MD) simulations, and in silico drug-likeness and ADME profiling to evaluate fourteen bioactive compounds against human AChE (hAChE, PDB: 6O4W) and Torpedo californica AChE (TcAChE, PDB: 1EVE). Docking analysis revealed binding affinities ranging from − 8.2 to − 11.2&#xa0;kcal/mol (hAChE) and − 8.1 to − 11.2&#xa0;kcal/mol (TcAChE), with Cepharadione A (NP1) exhibiting the highest affinity (− 11.2&#xa0;kcal/mol) via multiple stabilizing interactions within the active site. MD simulations confirmed the structural stability of NP1, NP2 (Savinin), and NP3 (Aristolactam II) complexes, with RMSD &lt; 2.0&#xa0;Å over 100&#xa0;ns. Drug-likeness and ADME evaluations indicated favorable pharmacokinetic properties, including optimal lipophilicity (LogP 1.84–5.0), high gastrointestinal absorption, and blood–brain barrier permeability. Most compounds demonstrated minimal P-glycoprotein efflux and selective metabolism via cytochrome P450 enzymes, supporting their CNS drug potential. Quantum chemical calculations further corroborated electronic stability and reactivity. These findings highlight <i>A. indica</i>-derived compounds as promising AChE inhibitors, addressing the need for safer and more effective natural alternatives for AD therapeutics and warranting further experimental validation.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Computational design and molecular insights into acetylcholinesterase inhibitors from Aristolochia indica for Alzheimer’s disease therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月24日

查看全文
  • Srinivasarao Mande,
  • Lalitha Repudi,
  • Sanchari Goswami,
  • Nadia Psalms Gangavarapu,
  • Hamid Ghaffoori Hasan,
  • Kumaraswamy Gandla

摘要

Alzheimer’s disease (AD) remains a major neurodegenerative disorder with limited effective treatments, necessitating the search for novel acetylcholinesterase (AChE) inhibitors to mitigate cognitive decline. While synthetic inhibitors pose concerns regarding toxicity and bioavailability, natural compounds from Aristolochia indica present a promising yet underexplored alternative. This study employed molecular docking, molecular dynamics (MD) simulations, and in silico drug-likeness and ADME profiling to evaluate fourteen bioactive compounds against human AChE (hAChE, PDB: 6O4W) and Torpedo californica AChE (TcAChE, PDB: 1EVE). Docking analysis revealed binding affinities ranging from − 8.2 to − 11.2 kcal/mol (hAChE) and − 8.1 to − 11.2 kcal/mol (TcAChE), with Cepharadione A (NP1) exhibiting the highest affinity (− 11.2 kcal/mol) via multiple stabilizing interactions within the active site. MD simulations confirmed the structural stability of NP1, NP2 (Savinin), and NP3 (Aristolactam II) complexes, with RMSD < 2.0 Å over 100 ns. Drug-likeness and ADME evaluations indicated favorable pharmacokinetic properties, including optimal lipophilicity (LogP 1.84–5.0), high gastrointestinal absorption, and blood–brain barrier permeability. Most compounds demonstrated minimal P-glycoprotein efflux and selective metabolism via cytochrome P450 enzymes, supporting their CNS drug potential. Quantum chemical calculations further corroborated electronic stability and reactivity. These findings highlight A. indica-derived compounds as promising AChE inhibitors, addressing the need for safer and more effective natural alternatives for AD therapeutics and warranting further experimental validation.

Graphical Abstract